You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION

    SBC: Acorda Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  2. DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE

    SBC: FEM CADET            Topic: N/A

    Chemoradiation improves survival for patients with locally advanced non-small cell lung cancer (NSCLC) over radiotherapy (R) alone. Les than 20% of patients have complete pathologic response to combination therapy. Paclitaxel (TXL) is effective as an anti-tumor agent and a radiosensitizer. Peripheral neurotoxicity and granulocytopenia limit its dosage; acute effects from TXL's infusion include na ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  3. CHROMOGENIC HER-2/NEU GENE AMPLIFICATION ASSAY

    SBC: NANOPROBES INC            Topic: N/A

    Overexpression of the Her-2/neu protein and amplification of the Her-2/neu gene are are the most widely accepted prognostic indicator of aggressive malignant behavior of invasive breast carcinoma. Accurate detection of Her-2/neu overexpression is critical in identifying patients suitable for serotherapy with humanized monoclonal antibody (Herceptin). Fluorescence in situ hybridization (FISH) has b ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  4. VALIDATION OF TRANSILLUMINATION AND THE NEVOSCOPE

    SBC: TRANSLITE            Topic: N/A

    DESCRIPTION (provided by applicant): Skin cancer is the most common of all cancers and melanoma is a deadly skin cancer that accounts for over 75% of all the skin cancer deaths in the United States. The incidence of melanoma is rising at approximately 3% per year. Early detection of melanoma results in 95% cure rate. But, early detection of melanoma is difficult because of the subtle changes that ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  5. ULTRASENSITIVE METHODS FOR HUMAN BIOMARKER QUANTITATION

    SBC: TRIANGLE LABORATORIES, INC.            Topic: N/A

    Basic research aimed at understanding the complex regulations and interactions lead to various diseases requires novel bioanalytical approaches that allow detailed characterization of the proteome with ultra high-speed and sensitivity so that important regulatory proteins can be effectively studied. For the analysis of complex protein mixtures such as cell lysates, two-dimensional polyacrylamide g ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  6. ASSAYS FOR ROS-INDUCED DNA DAMAGE

    SBC: ZEPTOMETRIX CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant):This project is a collaboration between ZeptoMetrix Corporation and Roswell Park Cancer Institute. The objective is to develop sensitive, quantitative and facile assays for measuring DNA damage caused by reactive oxygen species (ROS). ROS have been implicated in aging, cancer and several neurological diseases. Seven ROS-induced DNA lesions will be assayed, namel ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  7. GI SAFETY AND THERAPEUTICS OF OIL-BASED PC-NSAIDS

    SBC: GRASSROOTS PHARMACEUTICALS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The major objective of this Phase I STTR grant is to evaluate the GI safety, therapeutic activity and stability of a new class of non-steroidal anti-inflammatory drugs (NSAIDs) that are formulated with a soy bean oil that is enriched in phosphatidylcholine (PC). This represents a second generation of PC-NSAIDs, developed by the PI and associates, that would ha ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. BACILLUS ANTHRACIS CLONE SET

    SBC: SEQWRIGHT, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term aim of this project is to clone and express in E. coli all the genes from Bacillus anthracis, the causative agent of anthrax. This pathogen poses a serious biowarfare threat yet has been relatively understudied due to the low incidence of natural infection. An important first step would be to identify all antigenic proteins, vaccine candidates, th ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. LACTOFERRIN AS AN ADJUVANT FOR CELLULAR IMMUNITY

    SBC: Pharmareview Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop bovine and human Lactoferrins as an adjuvant to augment antibody and cell mediated immunity. We will specifically address the efficacy of Lactoferrin as an adjuvant to augment efficacy of BCG vaccination to subsequent challenge with virulent Mycobacterium tuberculosis. Improved nontoxic adjuvants, especially adj ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  10. ANTIMICROBIAL COATING FOR BIOFILM INHIBITION

    SBC: Biomedical Development Corporation            Topic: N/A

    Description(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that i ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government